Related Experiment Video
Updated: Mar 25, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
Behavioral and emerging pharmacologic treatment options for cognitive impairment in schizophrenia
Sophia Vinogradov1, S Charles Schulz
1From the Department of Psychiatry, University of California, San Francisco, and the San Francisco Department of Veterans Affairs Medical Center.
Abstract:
In recent years, the goal of treatment for individuals with schizophrenia has shifted from symptom control to functional recovery. For recovery to occur, the substantial cognitive impairments associated with this disorder must be addressed. Advances in neuroscience have paved the way for the development of more effective behavioral and pharmacologic treatments. Behavioral interventions such as cognitive training are tapping into the innate plasticity and adaptive qualities of the brain. Emerging pharmacologic treatments are targeting new neurotransmitters and systems, such as the glutamatergic system and the nicotinic-cholinergic system, which are involved in the cognitive and sensory deficits that lead to impairment. The best chances for recovery will most likely occur by combining behavioral and pharmacologic interventions.
More Related Videos
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
09:15The Attentional Set Shifting Task: A Measure of Cognitive Flexibility in Mice
Published on: February 4, 2015
Related Concept Videos
Alzheimer's Disease: Treatment
Psychosis: Goals of Pharmacotherapy
Drug Therapy
Antianxiety Medications
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Psychosis and Antipsychotic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents